- Home
- NTRB vs TCRX Comparison
NTRB vs TCRX Comparison
Compare NTRB & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | TCRX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 63.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NTRB | TCRX |
|---|---|---|
| Price | $4.00 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 10.6K | ★ 526.7K |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | $69.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $3.64 | $0.88 |
| 52 Week High | $11.68 | $2.57 |
Technical Indicators
Market Signals| Indicator | NTRB | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 47.18 |
| Support Level | N/A | $0.92 |
| Resistance Level | $4.50 | $1.23 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 33.72 | 25.00 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.